Global Vomiting Treatment Market, By Types (Posseting, Reflux, Projectile Vomiting), Mechanism of Action (Serotonin Antagonist, Antihistamine, D2 Receptors Antagonist, Benzodiazepine, Dopamine Antagonists, Others), Drugs (Ondansetron, Promethazine, Metoclopramide, Lorazepam, Others), Treatment (Medications, Rehydration, Others), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics, Others) – Industry Trends and Forecast to 2030.
Vomiting Treatment Market Analysis and Size
The rapid rise in prevalence of gastrointestinal disorders and the surge in cancer and chemotherapy treatment across the globe is expected to accelerate the market growth in the forecast period of 2023 to 2030. However, the lack of awareness amongst people regarding the causes of vomiting is projected to restrain the market growth rate. In addition, the growing research and development activities, increasing global healthcare expenditure and high adoption of healthcare solutions are likely to create various new opportunities that will impact this vomiting treatment market growth in the forecast period of 2023 to 2030.The patent expiry of branded drugs available are estimated to challenge the market’s growth.
Data Bridge Market Research analyses that the global vomiting treatment market which was USD 5,257.38 million in 2022, is expected to reach USD 8,331.62 million by 2030, and is expected to undergo a CAGR of 6.1% during the forecast period of 2023 to 2030. “Hospital” dominates the end-user segment of the global vomiting treatment market owing to the wide range of products applications there. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Vomiting Treatment Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015-2020)
Revenue in USD Million, Volumes in Units, Pricing in USD
Types (Posseting, Reflux, Projectile Vomiting), Mechanism of Action (Serotonin Antagonist, Antihistamine, D2 Receptors Antagonist, Benzodiazepine, Dopamine Antagonists, Others), Drugs (Ondansetron, Promethazine, Metoclopramide, Lorazepam, Others), Treatment (Medications, Rehydration, Others), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics, Others)
U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Merck & Co., Inc. (U.S.),Takeda Pharmaceutical Company Limited (Japan), Mylan N.V. (U.S.), GSK plc (U.K.), Sanofi (France), Pfizer Inc. (U.S.), Solvay (Belgium), Teva Pharmaceutical Industries Ltd. (Israel), Eisai Co., Ltd. (Japan), Kyowa Kirin Co., Ltd. (Japan), Baxter (U.S.), Sun Pharmaceutical Industries Ltd. (India), Glenmark Pharmaceuticals Inc. (India), Aurobindo Pharma (India), Fresenius SE & Co. KGaA (Germany), Hikma Pharmaceuticals PLC (U.K.), Accord Healthcare (U.K.), CASI Pharmaceuticals Inc. (U.S.)
Vomiting is a throwing up of the stomach food or contents out of the mouth. It basically a symptom of many conditions such as food poisoning, motion sickness, infection, migraines among other medical conditions. It can also be symptom of some serious diseases including liver disorders, brain tumours and heart attack among others.
Global Vomiting Treatment Market Dynamics
- Increasing Prevalence of Nausea and Vomiting
The occurrence of vomiting is prevalent in various medical conditions, such as chemotherapy-induced nausea and vomiting (CINV), morning sickness in pregnant women, and post-operative nausea and vomiting (PONV). The high prevalence of these conditions drives the demand for effective vomiting treatments. Such increasing cases with most of population in majority of countries contribute to treatment of these conditions which is expected to drive the global vomiting treatment market.
- Increase in Cancer Incidence
Increased in cancer incidence worldwide is predicted to favour the vomiting treatment demand as it is more prone to develop diseases. With the increasing incidence of cancer worldwide, chemotherapy-induced nausea and vomiting remain significant concerns for cancer patients. This drives the demand for antiemetic drugs to manage these side effects. Moreover, morning sickness is a common issue during pregnancy, and there is a constant need for safe and effective treatments, which can foster the demand for the vomiting treatment across the market.
- Increasing Patient-Centered Care Demand Elevates Treatment Customization
The growing demand for patient-centered care is a major driving factor shaping the nausea and vomiting treatment landscape. Patients are seeking treatments that not only alleviate symptoms but also consider their individual experiences, preferences, and medical histories.
This demand for personalized healthcare experiences is encouraging healthcare providers and pharmaceutical companies to develop treatments that are adaptable and tailored to each patient's needs. This cause-effect relationship leads to the development of treatment regimens that take into account factors such as patient sensitivity, medication tolerance, and potential interactions, ultimately fostering higher patient satisfaction, better adherence to treatment plans, and improved overall well-being.
- Increasing Advancements in Antiemetic Medications
Antiemetic drugs and medications have seen advancements, leading to more effective and better-tolerated treatments. New formulations and drug delivery methods have improved patient compliance and outcomes. This will extend profitable opportunities for the market players in the forecast period of 2023 to 2030.
Moreover, improvements in healthcare infrastructure in emerging markets have increased access to medical treatment, including vomiting management, which will further expand the market and lead to the growth of the vomiting treatment market in the above mentioned projected timeframe.
- Regulatory Hurdles Impacting Treatment Innovation
Complex landscape of regulatory hurdles is expected to restraint the market. The stringent regulatory requirements imposed on pharmaceuticals and medical treatments can pose challenges to the development and introduction of new treatments. Moreover, this restraint lies in the need for rigorous clinical trials, safety assessments, and regulatory approvals for any new medication or therapy. These stringent processes can prolong the timeline and increase the costs associated with bringing innovative treatments to market, resulting in potential breakthrough treatments which are expected to become the biggest and foremost challenge for the growth of the market in the forecast period of 2023-2030.
This global vomiting treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global vomiting treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
- In January 2023, Glenmark announced that the company has launches AKYNZEO I.V. for preventing chemotherapy induced nausea. AKYNZEO I.V. which is a fixed dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg), and is available as a ready-to-dilute I.V. This results in expanding products in the market.
Global Vomiting Treatment Market Scope
The global vomiting treatment market is segmented on the basis of types, mechanism of action, drugs, treatment, route of administration, distribution channel and end-users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Projectile Vomiting
Mechanism of Action
- Serotonin Antagonist
- D2 Receptors Antagonist
- Dopamine Antagonists
Route of Administration
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Specialty Clinics
Global Vomiting Treatment Market Regional Analysis/Insights
The global vomiting treatment market is analysed and market size insights and trends are provided by country, types, mechanism of action, drugs, treatment, route of administration, distribution channel and end-users as referenced above.
The countries covered in the global vomiting treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the global vomiting treatment market due to the availability of medicines for the treatment and highly developed health infrastructure
Asia-Pacific is expected to expand at a significant growth rate in the global vomiting treatment market during the forecast period of 2023 to 2030 due to rise in the population, changes in lifestyle and consumption of unhealthy diet in region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global vomiting treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global vomiting treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global vomiting treatment market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Vomiting treatment market Share Analysis
The global vomiting treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global vomiting treatment market.
Some of the major players operating in the global vomiting treatment market are:
- Merck & Co., Inc. (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Mylan N.V. (U.S.)
- GSK plc (U.K.)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- Solvay (Belgium)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Eisai Co., Ltd. (Japan)
- Kyowa Kirin Co., Ltd. (Japan)
- Baxter (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Glenmark Pharmaceuticals Inc. (India)
- Aurobindo Pharma (India)
- Fresenius SE & Co. KGaA (Germany)
- Hikma Pharmaceuticals PLC (U.K.)
- Accord Healthcare (U.K.)
- CASI Pharmaceuticals Inc. (U.S.)